Costco, Amgen, and GlycoNex join biosimilar competition

𝗧𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗡𝗲𝘄𝘀 𝟮𝟬𝟮𝟰 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles:   1. C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries https://lnkd.in/e7uWtea4 2. Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 https://lnkd.in/g63aR34M 3. The growing role for cfHPV-DNA testing in OPSCC therapeutic development https://lnkd.in/gqEtAytm 4. The Future of Precision Medicine: Leveraging Clinico-Genomic Data for Germline Disorders https://lnkd.in/gwCq8tZM 5. In the latest turn to autoimmune therapies, Cullinan nabs $280M to join the lupus space. https://lnkd.in/gBhi2j3T P.S. Comment below with the latest pharma/biotech news you came across. #pharma #cdmo #biotech

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: January 1 - 5, 2025 Regeneron acquires Oxular and gets hands on novel ocular drug delivery tech, BMS's Opdivo lands new approval for subcutaneous version, Roche in-licenses Innovent ADC in up to $1B deal, General Proximity launches with $16M to go after "undruggable" disease-linked proteins, Neumora stock collapses after navacaprant Ph3 failure in major depressive disorder + 31 more stories Get the full newsletter on the TLDR Biotech website: https://lnkd.in/gJ2_nV7a

The Pharma News 2025 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles: 1. BIOPHARMA Finishes 2024 Strong With ‘Robust’ VC, Upfront Payments: J.P. Morgan https://lnkd.in/gwfcF8nC 2. Tenvie Therapeutics Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases https://lnkd.in/gPz9DPNn 3. Navigating future biopharma catalysts: What to expect at the 2025 J.P. Morgan Healthcare Conference https://lnkd.in/gjkpPzCE 4. Letting go of ARMGO Pharma, Inc.: Biotech rebrands as RyCarma Therapeutics https://lnkd.in/gM8TNpGb 5. Wegovywire and Zepbound® (tirzepatide) Employer tipped to fuel $20B boom in heart failure market https://lnkd.in/gJit-Fnd P.S. Comment below with the latest pharma/biotech news you came across. #pharma #cdmo #biotech

Abliva AB has caught attention with a lucrative cash offer from Pharming Technologies, boasting a 227 percent premium, potentially unlocking new growth opportunities. Meanwhile, Infant Bacterial Therapeutics AB (IBT) is making waves in the neonatal care space, as it communicates its decision to launch its drug candidate IBP-9414, sending its stock up 35 percent. Read the newsletter here: https://lnkd.in/dnWMfca9

𝐃𝐫𝐮𝐠 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $19.5 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/djsDmmGj The size of global drug screening market in terms of revenue was estimated to be worth $9.1 billion in 2024 and is poised to reach $19.5 billion by 2029, growing at a CAGR of 16.6% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Labcorp Quest Diagnostics Abbott Thermo Fisher Scientific Alfa Scientific Designs, Inc. OraSure Technologies Siemens Healthineers Pensionskasse der F. Hoffmann-La Roche AG MPD, Inc. SHIMADZU CORPORATION Lifeloc Technologies Drägerwerk AG & Co. KGaA Premier Biotech Omega Laboratories Ltd. Psychemedics Corporation Clinical Reference Laboratory American Bio Medica Corporation (ABMC) ACM Global Laboratories CareHealth America Corp -A WHPM Company Sciteck, Inc. Intoximeters AccuSourceHR, Inc. Cordant Health Solutions Intoxalock Millennium Health

Multidisciplinary drug discovery company Argent BioPharma Ltd (LSE:MXC, OTC:RGTLF, ASX:RGT) has struck up a strategic collaboration with SINTEF, one of Europe’s largest independent research organisations, to tackle the critical clinical challenge of chronic wound management with shares trading higher as a result. The collaboration will help the biotech expand into new therapeutic areas with a focus on nano-formulations. Chronic wounds pose a major public health issue, inflicting severe suffering on patients and affecting large numbers of people around the world. These wounds present complex challenges such as antibiotic-resistant infections, impenetrable biofilms and deteriorating local tissue health. More at #Proactive #ProactiveInvestors #ASX #RGT #Biotech #Medtech #Health #Therapeutics http://ow.ly/mVmo105GhEG

#Researchers, how would you propose to progress intraocular drug delivery systems for the posterior eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutic modalities ranging from low molecular weight compounds to complex molecules. Learn more on #opnMe    https://lnkd.in/e-ETWpiF

Please check out this article on #atopicdermatitistreatment in a new interactive format! 👇 #atopicdermatitis

Nature’s Hidden Gems: Scorpion Venom & Vipera Lebetina Extracts Unlock groundbreaking possibilities in modern medicine with the extraordinary potential of Scorpion Venom and Vipera Lebetina extracts. These APIs are rich in bioactive components, offering innovations in cancer treatment, cardiovascular health, and more. With direct sourcing, unmatched quality, and a reliable supply chain, we prioritize trust, sustainability, and collaboration. 📩 Let’s connect! Message us to explore how these rare treasures can elevate your pharmaceutical innovations. Revolutionizing healthcare, one discovery at a time. #PharmaceuticalInnovation #ScorpionVenomAPI #ViperaLebetinaExtract #ActivePharmaceuticalIngredients #HealthcareSolutions #BiotechnologyResearch #ModernMedicine #R&DInnovation #PharmaExcellence #NatureInPharma #SustainableAPIs #MedicalBreakthroughs #DrugDevelopment #PharmaPartnerships #InnovativeHealthcare #i_daru #GlobalCollaboration #ModernMedicines

We're excited to share more exciting results from our latest study on SL-NAD+, iX Biopharma's novel sublingual NAD+ wafer. This pioneering research provides the first evidence that NAD+ can directly enter cells, setting a new standard for NAD+ supplementation. The study consisted of 3 parts: 2 single-dose PK studies and a multiple-dose PK study, conducted in 18 Sprague-Dawley rats. Key Findings: 1) First Evidence of Direct Cellular Entry: NAD+ can be transported in and out of cells, likely via connexin 43 hemichannels and solute carrier channels—challenging previous assumptions about its cellular uptake. 2) Rapid Absorption: A 2-fold increase in plasma NAD+ levels was observed within just 10 minutes, highlighting the efficiency of sublingual delivery. 3) Significant Bioavailability: SL-NAD+ showed a bioavailability of 22% compared to IV administration, offering a convenient alternative to intravenous NAD+ therapy. Dr Janakan Krishnarajah, COO & CMO of iX Biopharma, stated: "This study underscores our sublingual freeze-dried technology's ability to deliver NAD+ directly into cells, making it the new gold standard for NAD+ supplementation—no precursors needed." Stay tuned for more updates as we continue to lead the way in healthspan innovation! Janakan Krishnarajah Eva Tan Jeremy Dalton Daniel Chow #NAD #NMN #Antiaging #Healthspan #Wellness #Technology #Science #Innovation #Longevity #Pharmaceuticals #Supplements #PharmaceuticalInnovation #SublingualTechnology #Bioavailability